Key result
Animal venoms and salivary proteins inhibit platelet aggregation, aiding novel antiplatelet drug development.
Why the study?
Exogenous factors from animal sources that interfere with platelet aggregation have diverse mechanisms and structural features, and their study advances understanding of platelet aggregation and antiplatelet agent development.
Mechanistic and structure-function studies of animal-derived exogenous proteins have significantly contributed to understanding platelet aggregation and developing antiplatelet agents.
May inspire novel antiplatelet agents from animal proteins; leaves open clinical translation pending trials.
Platelet aggregation plays a crucial role in thrombosis. This review describes exogenous factors isolated from various animal sources, including venoms and the salivary glands that interfere in platelet aggregation. Some of these factors induce platelet aggregation or agglutination, whereas others inhibit platelet aggregation. These proteins range from small molecular weight peptides to large proteins. Some of these proteins exhibit various enzymatic activities, while others are nonenzymatic. These exogenous factors affect platelet aggregation by various mechanisms and thus they have been classified based on their mechanism of action. Many of these proteins have evolved through both convergent and divergent evolution. For example, platelet aggregation inhibitors, which interfere in the interactions between fibrinogen and its receptor, the glycoprotein IIb/IIIa complex, show extreme structural diversity but they share the common functional site of Arg-Gly-Asp (RGD) tripeptide segment. On the other hand, C-type lectin related proteins exhibit diverse biological effects by interacting with different proteins, but share common structural scaffold. Thus the mechanistic and structure-function studies of these exogenous proteins have contributed significantly to the understanding of molecular mechanisms of platelet aggregation and to the development of potent antiplatelet agents, respectively. A number of new exogenous factors have been identified recently and the search is still on for novel factors that interfere with platelet aggregation. Further studies in this area will help in the development of novel strategies for treating cardiovascular and hematological disorders.
No takes yet. Share an insight, caveat, or question.
R. Manjunatha Kini (2004) conducted a review in Thrombosis. Exogenous factors from animal sources (venoms and salivary glands) was evaluated. Exogenous factors from animal sources, including venoms and salivary gland proteins, interfere with platelet aggregation and contribute to the development of novel antiplatelet agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: